Launch of a New Formulation of Topina^®, an Antiepileptic Agent

Tokyo, Japan, May 1, 2014 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo; 4151 President and CEO: Nobuo Hanai; "Kyowa Hakko Kirin") announced today that Topina^® fine granules (Generic name: topiramate) will be launched in Japan May 13, 2014 as a new formulation.

Since the launch in September 2007, Topina^® Tablets have been used in adult epileptic patients for the treatment of partial onset seizures inadequately controlled with other antiepileptic drugs. In November 2013, the drug had been approved an additional dosage and administration for the treatment in pediatric epileptic patients aged two or older (as an adjunctive therapy with other antiepileptic drugs).

This new formulation, Topina^® fine granules, was listed on the National Health Insurance Drug Price List on April, 2014 after the manufacturing and marketing approval in Japan on January, 2014. The drug is more appropriate for administration in children and elderly people, and expected to improve the drug adherence.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Kyowa Hakko Kirin

Media Contact:

+81-3-3282-1903

or

Investors:

+81-3-3282-0009